文献速递心律失常血脂与心血管预防

房颤抗凝患者的肾脏结局比较

Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

该研究基于美国大型行政数据库关联实验室结果,纳入9769例非瓣膜性房颤患者,比较阿哌沙班、达比加群、利伐沙班与华法林对4项肾脏结局的影响。2年累积风险分别为eGFR下降≥30% 24.4%、血清肌酐翻倍4.0%、急性肾损伤14.8%、肾衰竭1.7%。汇总NOAC与华法林相比,eGFR下降≥30%、肌酐翻倍和AKI风险降低;达比加群和利伐沙班与部分肾脏结局改善相关,阿哌沙班无统计学显著关联。

要点

  • 房颤口服抗凝患者肾功能下降常见,2年eGFR下降≥30%累积风险24.4%。
  • 汇总NOAC较华法林降低eGFR下降≥30%、肌酐翻倍和AKI风险。
  • 达比加群和利伐沙班与部分肾脏结局改善相关,阿哌沙班无显著关联。

核心结论

  • NOACs,尤其是达比加群和利伐沙班,可能与华法林相比降低不良肾脏结局风险。

研究设计与样本

  • 使用美国大型行政数据库关联实验室结果,识别9769例非瓣膜性房颤患者,于2010年10月1日至2016年4月30日期间开始口服抗凝治疗。
  • 采用逆概率治疗加权平衡4个药物队列间60余项基线特征,并在加权人群中行Cox比例风险回归比较药物。

主要发现

  • 2年终点累积风险:eGFR下降≥30%为24.4%,血清肌酐翻倍为4.0%,AKI为14.8%,肾衰竭为1.7%。
  • 汇总3种NOAC与华法林相比:eGFR下降≥30% HR 0.77(95%CI 0.66-0.89,p<0.001),肌酐翻倍 HR 0.62(95%CI 0.40-0.95,p=0.03),AKI HR 0.68(95%CI 0.58-0.81,p<0.001)。
  • 与华法林相比,达比加群与较低的eGFR下降≥30%和AKI风险相关;利伐沙班与较低的eGFR下降≥30%、肌酐翻倍和AKI风险相关;阿哌沙班与任何肾脏结局均无统计学显著关系。

临床怎么用

  • 房颤患者选择口服抗凝药时,除卒中和出血风险外,可考虑药物对肾脏结局的潜在差异。
  • 达比加群和利伐沙班可能与较低的不良肾脏结局风险相关,阿哌沙班在本研究中未显示显著肾脏保护关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lifelong oral anticoagulation, either with warfarin or a non-vitamin K antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with atrial fibrillation (AF). Emerging evidence suggests that NOACs may be associated with better renal outcomes than warfarin. OBJECTIVES: This study aimed to compare 4 oral anticoagulant agents (apixaban, dabigatran, rivaroxaban, and warfarin) for their effects on 4 renal outcomes: ≥30% decline in estimated glomerular filtration rate (eGFR), doubling of the serum creatinine level, acute kidney injury (AKI), and kidney failure. METHODS: Using a large U.S. administrative database linked to laboratory results, the authors identified 9,769 patients with nonvalvular AF who started taking an oral anticoagulant agent between October 1, 2010 and April 30, 2016. Inverse probability of treatment weighting was used to balance more than 60 baseline characteristics among patients in the 4 drug cohorts. Cox proportional hazards regression was performed in the weighted population to compare oral anticoagulant agents. RESULTS: The cumulative risk at the end of 2 years for each outcome was 24.4%, 4.0%, 14.8%, and 1.7% for ≥30% decline in eGFR, doubling of serum creatinine, AKI, and kidney failure, respectively. When the 3 NOACs were pooled, they were associated with reduced risks of ≥30% decline in eGFR (hazard ratio [HR]: 0.77; 95% confidence interval [CI]: 0.66 to 0.89; p < 0.001), doubling of serum creatinine (HR: 0.62; 95% CI: 0.40 to 0.95; p = 0.03), and AKI (HR: 0.68; 95% CI: 0.58 to 0.81; p < 0.001) compared with warfarin. When comparing each NOAC with warfarin, dabigatran was associated with lower risks of ≥30% decline in eGFR and AKI; rivaroxaban was associated with lower risks of ≥30% decline in eGFR, doubling of serum creatinine, and AKI; however, apixaban did not have a statistically significant relationship with any of the renal outcomes. CONCLUSIONS: Renal function decline is common among patients with AF treated with oral anticoagulant agents. NOACs, particularly dabigatran and rivaroxaban, may be associated with lower risks of adverse renal outcomes than warfarin.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Yao X, Tangri N, Gersh BJ, et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017. PMID: 29169468. doi:10.1016/j.jacc.2017.09.1087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。